Cargando…
CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors
Mismatch repair-deficient (dMMR) tumors show a good response toward immune checkpoint inhibitors (ICI), but developing resistance impairs patients’ outcomes. Here, we compared the therapeutic potential of an α-PD-L1 antibody with the CDK4/6 inhibitor abemaciclib in two preclinical mouse models of dM...
Autores principales: | Salewski, Inken, Henne, Julia, Engster, Leonie, Krone, Paula, Schneider, Bjoern, Redwanz, Caterina, Lemcke, Heiko, Henze, Larissa, Junghanss, Christian, Maletzki, Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278458/ https://www.ncbi.nlm.nih.gov/pubmed/35845723 http://dx.doi.org/10.1080/2162402X.2022.2094583 |
Ejemplares similares
-
Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors
por: Salewski, Inken, et al.
Publicado: (2021) -
Short-term immune-checkpoint inhibition partially rescues perturbed bone marrow hematopoiesis in mismatch-repair deficient tumors
por: Krone, Paula, et al.
Publicado: (2023) -
Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors
por: Salewski, Inken, et al.
Publicado: (2021) -
The Individual Effects of Cyclin-Dependent Kinase Inhibitors on Head and Neck Cancer Cells—A Systematic Analysis
por: Schoenwaelder, Nina, et al.
Publicado: (2021) -
Preclinical Head and Neck Squamous Cell Carcinoma Models for Combined Targeted Therapy Approaches
por: Schoenwaelder, Nina, et al.
Publicado: (2022)